Treating to New Targets (TNT) Study: Does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit?

American Journal of Cardiology

Volumn 93, Issue 2, 2004, Pages 154-158

  Waters, David D ^a   Guyton, John R ^b   Herrington, David M ^b   McGowan, Mary P ^b   Wenger, Nanette K ^b   Shear, Charles ^b  

^a SAN FRANCISCO GENERAL HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; FOLLOW UP; HEART ARREST; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; STROKE; TREATMENT OUTCOME;

EID: 0346962889     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2003.09.031     Document Type: Article

References (8)

1. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 285:2001;2486-2497.
2. Management of dyslipidemia in adults with diabetes. Diabetes Care. 22:(suppl 1):1999;S56-S59.
3. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20, 536 high-risk individuals a randomised placebo-controlled trial . Lancet. 360:2002;7-22.
4. Grundy S.M. Statin trials and goals of cholesterol-lowering therapy. Circulation. 97:1998;1436-1439.
5. Jones P.H. Lipid-lowering treatment in coronary artery disease how low should cholesterol go? Drugs. 59:2000;1127-1135.
6. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease the Scandinavian Simvastatin Survival Study (4S) . Lancet. 344:1994;1383-1389.
7. Sacks F.M., Pfeffer M.A., Moyé L.A., Rouleau J.L., Rutherford J.D., Cole T.G., Brown L., Warnica J.W., Arnold J.M.O., Wun C.C., Davis B.R., Braunwald E.B. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 335:1996;1001-1009.
8. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 339:1998;1349-1357.